faller, bernard
faller, bernard
Director, Global Discovery ADME, Novartis
Verified email at
Cited by
Cited by
Coexistence of passive and carrier-mediated processes in drug transport
K Sugano, M Kansy, P Artursson, A Avdeef, S Bendels, L Di, GF Ecker, ...
Nature reviews Drug discovery 9 (8), 597-614, 2010
High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes
F Wohnsland, B Faller
Journal of medicinal chemistry 44 (6), 923-930, 2001
Alkylamides from Echinacea are a new class of cannabinomimetics: cannabinoid type 2 receptor-dependent and-independent immunomodulatory effects
S Raduner, A Majewska, JZ Chen, XQ Xie, J Hamon, B Faller, ...
Journal of Biological Chemistry 281 (20), 14192-14206, 2006
PAMPA—critical factors for better predictions of absorption
A Avdeef, S Bendels, L Di, B Faller, M Kansy, K Sugano, Y Yamauchi
Journal of pharmaceutical sciences 96 (11), 2893-2909, 2007
Modeling promiscuity based on in vitro safety pharmacology profiling data
K Azzaoui, J Hamon, B Faller, S Whitebread, E Jacoby, A Bender, ...
ChemMedChem: Chemistry Enabling Drug Discovery 2 (6), 874-880, 2007
Drug permeability profiling using cell-free permeation tools: Overview and applications
P Berben, A Bauer-Brandl, M Brandl, B Faller, GE Flaten, AC Jacobsen, ...
European Journal of Pharmaceutical Sciences 119, 219-233, 2018
Computational approaches to determine drug solubility
B Faller, P Ertl
Advanced drug delivery reviews 59 (7), 533-545, 2007
Evidence-based approach to assess passive diffusion and carrier-mediated drug transport
L Di, P Artursson, A Avdeef, GF Ecker, B Faller, H Fischer, JB Houston, ...
Drug discovery today 17 (15-16), 905-912, 2012
Passive lipoidal diffusion and carrier-mediated cell uptake are both important mechanisms of membrane permeation in drug disposition
D Smith, P Artursson, A Avdeef, L Di, GF Ecker, B Faller, JB Houston, ...
Molecular pharmaceutics 11 (6), 1727-1738, 2014
4‐[3, 5‐Bis (2‐hydroxyphenyl)‐1, 2, 4‐triazol‐1‐yl]‐benzoic acid: a novel efficient and selective iron (III) complexing agent
U Heinz, K Hegetschweiler, P Acklin, B Faller, R Lattmann, HP Schnebli
Angewandte Chemie International Edition 38 (17), 2568-2570, 1999
Artificial membrane assays to assess permeability
B Faller
Current drug metabolism 9 (9), 886-892, 2008
Metabolic soft spot identification and compound optimization in early discovery phases using MetaSite and LC-MS/MS validation
M Trunzer, B Faller, A Zimmerlin
Journal of medicinal chemistry 52 (2), 329-335, 2009
The Identification of Indacaterol as an Ultralong-Acting Inhaled β2-Adrenoceptor Agonist
F Baur, D Beattie, D Beer, D Bentley, M Bradley, I Bruce, SJ Charlton, ...
Journal of medicinal chemistry 53 (9), 3675-3684, 2010
What is modulating solubility in simulated intestinal fluids?
G Ottaviani, DJ Gosling, C Patissier, S Rodde, L Zhou, B Faller
European journal of pharmaceutical sciences 41 (3-4), 452-457, 2010
Heparin-induced conformational change and activation of mucus proteinase inhibitor
B Faller, Y Mely, D Gerard, JG Bieth
Biochemistry 31 (35), 8285-8290, 1992
ICL670A: preclinical profile
H Nick, A Wong, P Acklin, B Faller, Y Jin, R Lattmann, T Sergejew, ...
Iron Chelation Therapy, 185-203, 2002
Heparin strongly decreases the rate of inhibition of neutrophil elastase by alpha 1-proteinase inhibitor
KJ Frommherz, B Faller, JG Bieth
Journal of Biological Chemistry 266 (23), 15356-15362, 1991
CYP3A time-dependent inhibition risk assessment validated with 400 reference drugs
A Zimmerlin, M Trunzer, B Faller
Drug metabolism and disposition 39 (6), 1039-1046, 2011
Finasteride: A slow-binding 5. alpha.-reductase inhibitor
B Faller, D Farley, H Nick
Biochemistry 32 (21), 5705-5710, 1993
New approach to measure protein binding based on a parallel artificial membrane assay and human serum albumin
E Lázaro, PJ Lowe, X Briand, B Faller
Journal of medicinal chemistry 51 (7), 2009-2017, 2008
The system can't perform the operation now. Try again later.
Articles 1–20